Trial
NCT04358068
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Teva Pharmaceutical Industries, Ltd.
Condition
COVID-19
Intervention
Hydroxychloroquine (HCQ)
Why stopped
Slow enrollment and lack of community enthusiasm
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-16